Last update Sept. 23, 2023

イカチバント酢酸塩

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

Icatibant is a bradykinin B2 receptor antagonist used to treat acute episodes of swelling and inflammation associated with hereditary angioedema. Administration by subcutaneous injection 1 to 3 times on the same day.

At the date of the last update we found no published data on its excretion in breast milk.

Its high molecular weight makes it unlikely to pass into breast milk.

Due to its protein nature, it is inactivated in the gastrointestinal tract, not being absorbed (oral bioavailability practically null), which hinders or prevents its passage to infant plasma from ingested breast milk, except in premature infants and immediate neonatal period, in which there may be greater intestinal permeability.

No problems have been observed in infants born to a mother treated with icatibant for many months. (Kondo 2023)

Pending further published data on this drug in relation to lactation, known safer alternatives may be preferable, especially during the neonatal period and in case of prematurity. (Yeich 2023, Bouillet 2015)

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

イカチバント酢酸塩 is Icatibant Acetate in Japanese.

Is written in other languages:

Group

イカチバント酢酸塩 belongs to this group or family:

Tradenames

Main tradenames from several countries containing イカチバント酢酸塩 in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. ≈ 0 %
Molecular weight 1.364 daltons
Protein Binding 44 %
VD 0.4 l/Kg
pKa 3.46 -
Tmax 0.75 hours
T½ 1.4 ± 0.4 hours

References

  1. Kondo Y, Yoshimura A, Azuma N. Successful management of hereditary angioedema with icatibant during the postpartum period. Journal of Cutaneous Immunology and Allergy. 2023;6:26–27. Consulted on Sept. 22, 2023 Abstract Full text (link to original source)
  2. Yeich A, Elhatw A, Ashoor Z, Park K, Craig T. Safety of medications for hereditary angioedema during pregnancy and lactation. Expert Opin Drug Saf. 2023 Jan;22(1):17-24. Consulted on Sept. 22, 2023 Abstract
  3. Takeda. Icatibant. Drug Summary. 2020 Full text (in our servers)
  4. Bouillet L, Lehmann A, Gompel A, Boccon-Gibod I, Launay D, Fain O; CREAK.. Traitements des angiœdèmes héréditaires : recommandations du centre de référence national des angiœdèmes (consensus 2014 de Bordeaux). [Hereditary angiœdema treatments: Recommendations from the French national center for angiœdema (Bordeaux consensus 2014)]. Presse Med. 2015 Abstract
  5. EMA. Icatibant. Ficha técnica. 2013 Full text (in our servers)

Total visits

233

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by La Liga de la Leche de México of Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM